TP53 and breast cancer: In TP53 mutant tumors, we observed a significant enrichment (FDR < 0.05) of CK2, known to inhibit TP53 tumor suppressor function [69], AMPKA1, known to inhibit autophagy in PDAC and breast cancer [70], ERK1, LATS1, AKT1, and GSK3A kinase signaling and activity (Fig. 4D,E).